| miR-221 |
Upregulated |
Tamoxifen |
P27 kip1 |
Enhances proliferation and invasion |
56
|
| miR-155 |
Upregulated |
Doxorubicin |
FOXO |
Promotes proliferation and reduces apoptosis |
57
|
| miR-30b |
Upregulated |
Trastuzumab |
CCNE2 |
Induces the apoptosis pathway |
58
|
| miR-26a |
Upregulated |
Trastuzumab |
CCNE2 |
Induces the apoptosis pathway |
58
|
| miR-21 |
Upregulated |
Trastuzumab |
PTEN, PDCD4 |
Cell survival, apoptosis, resistance to systemic therapy |
59
|
| miR-107 |
Downregulated |
Paclitaxel |
E2F1 |
Promotes apoptosis |
60
|
| miR-7 |
Downregulate |
Trastuzumab |
EGFR |
Induces cell proliferation and metastasis |
61
|
| miR-128 |
Upregulated |
Letrozole |
TGBR1 |
Growth inhibitory effect of TGFβ |
62
|
| miR-214 |
Downregulated |
Tamoxifen |
UCP2 |
Inhibition of autophagy |
63
|
| miR-159 |
Upregulated |
Doxorubicin |
Wnt |
Promotes apoptosis |
64
|
| miR-16 |
Upregulated |
Doxorubicin |
Bcl-2 |
Induces tumor cell apoptosis |
65
|
| miR-298 |
Upregulated |
Doxorubicin |
P-gp |
Alters MDR modulation |
66
|
| miR-302b |
Downregulated |
Cisplatin |
E2F1 |
Inhibit cell cycle progression |
67
|
| Let-7a |
Upregulated |
Paclitaxel |
ABCB10 |
Promotes invasion and autophagy |
68
|
| miR-375 |
Downregulated |
Trastuzumab |
IGF1R |
Reverse EMT |
69
|
| miR-125 |
Downregulated |
Trastuzumab |
ERBB2, ERBB3 |
Reverse EMT |
70
|
| miR-200c |
Downregulated |
Trastuzumab |
ZNF217, ZEB1 |
Inhibit TGF-β signaling |
71
|
| miR-27b |
Downregulated |
Tamoxifen |
HMGB3 |
Promotes apoptosis |
72
|
| miR-124 |
Upregulated |
Doxorubicin |
STAT3 |
Resists the mechanism of cancer stem cells |
73
|
| miR-199b |
Downregulated |
Trastuzumab |
HER2 |
Inhibits ERK1/2 and AKT pathways |
74
|